Holen Sie sich die Stockscreener-App
118.29
0.03%
0.076
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$118.21
Offen:
$117.515
24-Stunden-Volumen:
4.12M
Relative Volume:
0.64
Marktkapitalisierung:
$146.74B
Einnahmen:
$28.80B
Nettoeinkommen (Verlust:
$6.31B
KGV:
23.53
EPS:
5.0273
Netto-Cashflow:
$9.37B
1W Leistung:
+1.25%
1M Leistung:
+3.23%
6M Leistung:
+11.03%
1J Leistung:
+39.03%
1-Tages-Spanne:
$116.62
$119.33
1-Wochen-Bereich:
$115.75
$119.33
52-Wochen-Spanne:
$84.80
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
118.26 | 146.68B | 28.80B | 6.31B | 9.37B | 5.0273 |
|
LLY
Lilly Eli Co
|
812.40 | 734.56B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.74 | 459.75B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
229.08 | 406.84B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.38 | 249.96B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
85.01 | 214.06B | 63.43B | 16.42B | 14.72B | 6.4861 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Chinese Research Org. Says Gilead Infringed COVID Patent - Law360
Gilead and Arcus see survival boost with gastric cancer combo - The Pharma Letter
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga
Gilead to present promising data for Trodelvy in breast cancer at ESMO - Investing.com
Gilead to present Trodelvy breast cancer data at ESMO 2025 - StreetInsider
Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades' - Benzinga
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025 - Business Wire
Yousif Capital Management LLC Sells 2,855 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Survival data boost prospects for Gilead, Arcus TIGIT drug in gastric cancer - FirstWord Pharma
ADAPT: Accelerating Disability Awareness & Progress Together - Gilead Sciences
OFI Invest Asset Management Sells 86,817 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Transcendent Capital Group LLC Invests $432,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Position Boosted by Sivik Global Healthcare LLC - MarketBeat
Natural Investments LLC Has $317,000 Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Lmcg Investments LLC Has $1.97 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline - Yahoo
Conning Inc. Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Fourpath Capital Management LLC Reduces Stake in Gilead Sciences, Inc. $GILD - MarketBeat
3Chopt Investment Partners LLC Acquires 3,318 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Aberdeen Group plc - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Unloaded Rep. Val T. Hoyle - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Gilead: Incorporating Longer Biktarvy Runway - Morningstar
Gilead's HIV Portfolio Has a Long Runway and Supports a Wide Moat - Morningstar
Cantor Fitzgerald Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Blair William & Co. IL Decreases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Trifecta Capital Advisors LLC Has $339,000 Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
TFR Capital LLC. Makes New $283,000 Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Callan Family Office LLC Purchases 63,300 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Tectonic Advisors LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Maryland State Retirement & Pension System Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
US Bancorp DE Sells 22,670 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Vontobel Holding Ltd. Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Can Gilead Sciences Inc. hit a new high this monthWeekly Investment Report & Fast Moving Trade Plans - newser.com
Real time social sentiment graph for Gilead Sciences Inc.July 2025 Setups & Weekly Breakout Stock Alerts - newser.com
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025 - BioSpace
"Taking possibility back" across oncology’s toughest frontiers - statnews.com
Gilead Sciences To Release Third Quarter 2025 Financial Results On Thursday, October 30, 2025 - TradingView
Gilead blocks HIV drug generics for more than 10 years - Life Sciences Intellectual Property Review
A Look Inside Gilead's Inflammation Pipeline - Gilead Sciences
Cantor Fitzgerald Adjusts PT on Gilead Sciences to $135 From $129, Maintains Overweight Rating - MarketScreener
Can Gilead Sciences Inc. stock deliver consistent earnings growthMarket Trend Summary & Real-Time Market Sentiment Reports - newser.com
Fluent Financial LLC Raises Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Kingswood Wealth Advisors LLC Reduces Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Given "Buy (B)" Rating at Weiss Ratings - MarketBeat
Citigroup Maintains Gilead Sciences (GILD) Buy Recommendation - Nasdaq
Gilead Sciences Rallies After Trump Partnership News Is the Growth Story Just Beginning - Yahoo Finance
GILD: Citigroup Raises Price Target for Gilead Sciences Amid Buy Rating | GILD Stock News - GuruFocus
Greed Is a Hell of a Drug - Truthdig
Multiple Myeloma CAR-T Market Set for Rapid Growth Driven by BCMA-Targeted Therapies and Innovative Advances - GlobeNewswire Inc.
RBC Capital raises Gilead Sciences stock price target to $100 on Yeztugo launch - Investing.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):